Gilead Announces Response Data from Phase 2 Study of Idelalisib for ... MarketWatch (press release) Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ... |
